ClinicalTrials.gg
RecruitingNCT07129993Updated Aug 20, 2026

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

A Phase 2/3 interventional study of Dato-DXd and Carboplatin in Urothelial Cancer and Bladder Cancer, sponsored by Daiichi Sankyo. Recruiting at 100 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Daiichi Sankyo · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
630
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 881 studies in Urinary Bladder Neoplasms with a site in United States — 162 open to participants now, 267 under way, 31 of them phase 3. Urinary Bladder Neoplasms · United States.

Planned enrollment
35th of 714
630 · median 46
Started
2025
with 53 others
Phase 2/3
9 of 881
2 open now
Primary completion
2029-06
later than 225 of 264 live
Registered
826th of 881
by date

Among the 881 studies in Urinary Bladder Neoplasms with a site in United States, this one is the 35th largest by planned enrollment of the 714 interventional ones that give a count, is one of 54 that started in 2025, is one of 9 in phase 2/3, reaches primary completion later than 225 of the 264 other live ones, and was the 826th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

162 of the 881 studies in Urinary Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 881 studies in Urinary Bladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progressed during or after EV plus pembrolizumab combination treatment.

This trial will start with part A, Phase 2. During part A, Phase 2, preliminary efficacy and safety will be assessed, and the recommended Phase 3 dose (RP3D) will be identified when the data allow sufficient assessment of activity, safety, and tolerability. The Phase 3 part will start contingent upon the assessment in the Phase 2 part, taking into consideration the totality of information.

03

Conditions studied

  • Urothelial Cancer
  • Bladder Cancer

Keywords

  • Urothelial Carcinoma
  • Dato-DXd
  • TROPION
  • DS-1062a
  • Datopotamab Deruxtecan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Adult ≥18 years at the time the ICF is signed (if the legal age of consent is > 18 years old, then follow the local regulatory requirements).
  • or cytologically confirmed unresectable or locally advanced (T4b, any N; or any T, N 2-3) or (any T, any N, M1) urothelial carcinoma of the bladder, renal pelvis, ureter, or urethra. Participants with urothelial carcinoma (transitional cell) with squamous differentiation or mixed cell types are eligible if the histology is predominantly urothelial as specified in the protocol.
  • Must provide tumor tissue sample from or newly obtained pretreatment biopsy for exploratory biomarker testing. Tumor tissue sample should not be collected from a lesion that was irradiated unless documentation can be provided confirming that the tumor tissue was collected at least 3 months after radiation and the lesion increased/appeared since radiation occurred. Tumor tissue must be of sufficient quantity (as defined in the Laboratory Manual).
  • Archival tissue collected after the most recent anticancer treatment and within 12 months before the date is preferred.
  • Must be considered eligible to receive cisplatin- or carboplatin-containing chemotherapy, in the investigator's judgment. Participants eligible for cisplatin will receive cisplatin. If a participant received gemcitabine, carboplatin, or cisplatin for early UC in the /neoadjuvant setting, the decision to rechallenge the participant with platinum therapy will be at the discretion of the investigator. Participants only receive carboplatin if they are ineligible for cisplatin. Participants are cisplatin-ineligible if they meet any of the following criteria: a. \<60 mL/min (GFR may be estimated by calculated using the Cockcroft-Gault formula, Modification of Diet in Renal Disease, or 24-hour urine)

For Phase 2 part:

  • Participants with a GFR \<60 mL/min but ≥50 mL/min but have no other cisplatin ineligibility criteria (items b, c, and d) may be considered cisplatin-eligible based on the investigator's clinical judgment.

For Phase 3 Part:

  • Participants with borderline renal function CrCl ≥40 mL/min to \<60 mL/min who have no other cisplatin ineligibility criteria (items b, c, and d) may receive cisplatin using a split-dose regimen, administered as cisplatin 35 mg/m\^2 on Days 1 and 8 of each 21-day cycle, for a maximum of 4 to 6 cycles.
  • In participants with CrCl ≥50 mL/min to \<60 mL/min, full-dose cisplatin may also be administered at the investigator's discretion, based on the overall clinical assessment.

The dosing schedule and dose level for Dato-DXd or gemcitabine are not altered when combined with either split-dose or full-dose cisplatin.

For both Phase 2 and Phase 3:

b. Grade ≥2 audiometric hearing loss c. NCI-CTCAE Grade ≥2 peripheral neuropathy d. Class III heart failure

  • Must have experienced radiographic progression or relapse during or after 1L of EV (or other agents with a vedotin payload) and pembrolizumab (or other /PD-L1 inhibitors).

Participants who discontinued EV (or other agents with a vedotin payload) and pembrolizumab (or other PD-1/PD-L1 inhibitors) in 1L due to toxicity are eligible if they have experienced disease progression following discontinuation. Participant who received EV (or other agents with a vedotin payload) plus pembrolizumab (or other PD-1/PD-L1) inhibitors in a neoadjuvant/adjuvant setting and progressed during treatment or within 12 months of treatment completion will also be considered for enrollment, after approval by the Sponsor's Medical Monitor or Sponsor's designee.

Key Exclusion Criteria:

  • Has had prior systemic therapy other than the combination of EV and pembrolizumab for la/mUC. The following participants may be considered eligible after approval by the Sponsor's Medical Monitor or Sponsor's designee.
  • Participant who progressed during or after treatments with assets that include either anti-Nectin 4 or vedotin payload (MMAE or other microtubule inhibitors) combined with PD1/PD-L1 inhibitors in 1L la/mUC.
  • Treatment with any of the following:

    1. History of an allogeneic bone marrow or solid organ transplant.
    2. Concomitant treatment with any prohibited medications in this protocol.
    3. Prior TROP2 directed ADC therapy.
  • Uncontrolled or significant cardiovascular disease, including:

interval >470 ms based on the average of triplicate 12-lead ( per local read) at screening.

  1. Screening myocardial infarction within 6 months prior to randomization.
  2. Uncontrolled angina pectoris within 6 months prior to randomization.
  3. NYHA Class 3 or 4 congestive heart failure at screening.
  4. Uncontrolled hypertension (resting systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg within 28 days before randomization that is not resolved despite maximal medical therapy).

    • Has a history of non-infectious ILD/pneumonitis including radiation pneumonitis that required , has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
    • Has clinically severe pulmonary compromise as judged by the investigator resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (eg, severe asthma, severe , restrictive lung disease, pleural effusion, etc.) or any , connective tissue, or inflammatory disorders with pulmonary involvement (eg, rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc.), or prior complete pneumonectomy.
    • Toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet improved to NCI-CTCAE version 5.0 Grade ≤1 or baseline. Note: Participants may be enrolled with chronic, stable Grade 2 toxicities (defined as no worsening to Grade >2 for at least 3 months prior to randomization and managed with standard of care treatment) which the investigator deems related to previous anticancer therapy, comprised of (including but not limited to):

a. Anticancer therapy-induced neuropathy b. Residual toxicities from prior immunotherapy treatment: Grade 1 or Grade 2 endocrinopathies which may include:

  • Hypothyroidism/ hyperthyroidism
  • Type I diabetes
  • Hyperglycemia
  • Adrenal insufficiency
  • Adrenalitis c. Skin hypopigmentation (vitiligo)
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
630 participants (estimated)

Study arms

  • Experimental
    Part A (Phase 2): Dato-DXd, 4 mg/kg with Platinum

    Participants will receive Dato-DXd in combination with platinum (carboplatin or cisplatin). The RP3D will be determined using data collected from Part A.

    Drug: Dato-DXd · Drug: Carboplatin · Drug: Cisplatin

  • Experimental
    Part A (Phase 2): Dato-DXd, 6 mg/kg with Platinum

    Participants will receive Dato-DXd in combination with platinum (carboplatin or cisplatin). The RP3D will be determined using data collected from Part A.

    Drug: Dato-DXd · Drug: Carboplatin · Drug: Cisplatin

  • Experimental
    Part B (Phase 3): Dato-DXd, RP3D with Platinum

    Participants will receive Dato-DXd at the RP3D in combination with platinum (carboplatin or cisplatin).

    Drug: Dato-DXd · Drug: Carboplatin · Drug: Cisplatin

  • Active comparator
    Part B (Phase 3): Gemcitabine with Platinum

    Participants will receive Gemcitabine in combination with platinum (carboplatin or cisplatin).

    Drug: Carboplatin · Drug: Cisplatin · Drug: Gemcitabine

Interventions

  • Dato-DXd will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of 4 mg/kg or 6 mg/kg in Part A or RP3D in Part B

    Also known as: Datopotamab Deruxtecan

  • Carboplatin will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of AUC 4.5 or 5.0 mg•min/mL

  • Cisplatin will be administered as an intravenous (IV) infusion every three weeks (Q3W) at a dose of 70 mg/m\^2 (Phase 2) or 70 mg/m\^2 on Day 1 or 35 mg/m\^2 on Day 1 and Day 8 each 21- day cycle (Phase 3)

  • Gemcitabine will be administered as an IV infusion at a dose of 1000 mg/m\^2 on Day 1 and 8 of every 3 week cycle.

06

What researchers measure

Primary outcomes

  1. Overall Response Rate - Part A (Phase 2)

    Overall Response Rate (ORR) is defined as the proportion of participants with a Best Overall Response (BOR) of confirmed Complete Response (CR) or confirmed Partial Response (PR). As assessed by investigator per RECIST v1.1

    Time frame: From Phase 2 randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, up to approximately 34 months

  2. Progression Free Survival as Assessed by Blinded Independent Central Review (BICR) - Part B (Phase 3)

    Progression Free Survival (PFS) is defined as the time from randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first. As assessed by BICR per RECIST v1.1

    Time frame: From Phase 3 randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, up to approximately 38 months

  3. Overall Survival - Part B (Phase 3)

    Overall Survival (OS) is defined as the time from randomization to death due to any cause.

    Time frame: From Phase 3 randomization to death due to any cause, up to approximately 38 months

Secondary outcomes

  1. Duration of Response - Part A (Phase 2)

    Duration of Response (DoR) is defined as the time from the date of first documentation of objective tumor response (confirmed CR or confirmed PR) to the date of the first documented radiographic disease progression or death due to any cause, whichever occurs first in responding participants. As assessed by investigator per RECIST v1.1

    Time frame: From the date of first documentation of objective tumor response to the date of the first documented radiographic disease progression or death due to any cause, whichever occurs first in Phase 2, up to approximately 34 months

  2. Progression Free Survival as Assessed by Investigator - Part B (Phase 3)

    PFS is defined as the time interval from the date of randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first. As assessed by investigator per RECIST v1.1

    Time frame: From Phase 3 randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, up to approximately 38 months

  3. Overall Response Rate - Part B (Phase 3)

    ORR is defined as the proportion of participants with a BOR of confirmed CR or confirmed PR. As assessed by BICR and investigator per RECIST V1.1

    Time frame: From Phase 3 randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, up to approximately 38 months

07

Study locations

29 of 100 sites recruiting
  • Research Site
    Fullerton, California 92835, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Glendale, California 91204, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    La Jolla, California 92093, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Los Angeles, California 90024, United States
    Recruiting
  • Research Site
    Orange, California 92868, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    San Francisco, California 94158, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Aurora, Colorado 80012, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Orange City, Florida 32763, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    St. Petersburg, Florida 33701, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Tamarac, Florida 62269, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Atlanta, Georgia 30342, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Locust Grove, Georgia 30248, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Effingham, Illinois 62401, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Niles, Illinois 60714, United States
    Recruiting
  • Research Site
    Peoria, Illinois 61615, United States
    Recruiting
  • Research Site
    Largo, Maryland 20774, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Boston, Massachusetts 02216, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Grand Rapids, Michigan 49546, United States
    Recruiting
  • Research Site
    Rochester, Minnesota 55905, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    St Louis, Missouri 63110, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    New York, New York 10029, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Chapel Hill, North Carolina 27514, United States
    Recruiting
  • Research Site
    Raleigh, North Carolina 27610, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Portland, Oregon 97227, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Monroeville, Pennsylvania 15146, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Philadelphia, Pennsylvania 19107, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Providence, Rhode Island 02906, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Myrtle Beach, South Carolina 29572, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Germantown, Tennessee 38138, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Memphis, Tennessee 38120, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Nashville, Tennessee 37203, United States
    Recruiting
  • Research Site
    Austin, Texas 33322, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Dallas, Texas 75246, United States
    Recruiting
  • Research Site
    Dallas, Texas 75390, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Charlottesville, Virginia 22908, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Norfolk, Virginia 23502-1871, United States
    Recruiting
  • Research Site
    Spokane, Washington 99208, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Madison, Wisconsin 53715, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Graz, 8036, Austria
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Krems, Austria
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Linz, 4010, Austria
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Salzburg, 5020, Austria
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Vienna, Austria
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Beijing, 100142, China
    Recruiting
  • Research Site
    Chengdu, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Guangzhou, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Angers, 49055, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Bordeaux, 33075, France
    Recruiting
  • Research Site
    Brest, France
    Recruiting
  • Research Site
    Calais, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Cedex 10, France
    Recruiting
  • Research Site
    Créteil, France
    Recruiting
  • Research Site
    Grenoble, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    La Chaussée-Saint-Victor, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    La Roche-sur-Yon, France
    Recruiting
  • Research Site
    Le Mans, France
    Recruiting
  • Research Site
    Lyon, France
    Recruiting
  • Research Site
    Marseille, 13273, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Marseille, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Montpellier, France
    Recruiting
  • Research Site
    Nantes, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Nîmes, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Paris, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Paris, France
    Recruiting
  • Research Site
    Pierre-Bénite, 69310, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Poitiers, France
    Recruiting
  • Research Site
    Quint-Fonsegrives, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Reims, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Saint-Etienne, France
    Recruiting
  • Research Site
    Saint-Herblain, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Strasbourg, 67065, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Toulouse, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Vandœuvre-lès-Nancy, France
    Recruiting
  • Research Site
    Eisleben Lutherstadt, 06295, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Herne, 44625, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Nürtingen, Germany
    Recruiting
  • Research Site
    Stuttgart, 70174, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Naples, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Roma, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Rozzano, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Bunkyō City, 113-8519, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Bunkyō City, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Fukuoka, 812-8582, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Fukuoka, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Hirosaki-shi, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Kanazawa, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Kawasaki, Japan
    Recruiting
  • Research Site
    Kōtoku, 135-8550, Japan
    Recruiting
  • Research Site
    Kumamoto, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Kyoto, 606-8507, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Nagoya, Japan
    Recruiting
  • Research Site
    Niigata, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Okayama, 700-8558, Japan
    Recruiting
  • Research Site
    Osaka, Japan
    Recruiting
  • Research Site
    Osakasayama-shi, 589-8511, Japan
    Recruiting
  • Research Site
    Sapporo, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Shinjuku-ku, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Toyama, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Tsukuba, 305-8576, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Ube-shi, 755-8505, Japan
    Recruiting
08

References and documents

Publications

  • Galsky MD, Drakaki A, Basu A, McGregor B, Bedke J, Loriot Y, Kikuchi E, Guo J, Garmezy B, Sridhar SS, Singh P, Koshkin VS, Fleming M, Klauss G, Lin D, Liu C, Apolo AB, Powles T. TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma. Future Oncol. 2026 May;22(12):1387-1396. doi: 10.1080/14796694.2026.2663956. Epub 2026 May 16. PubMed 42142358 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Completed studies that have reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Jun 2029, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2025
First posted
Aug 19, 2025
StartActual
Sep 26, 2025
Primary completionEst.
Jun 1, 2029
CompletionEst.
Jan 22, 2030
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07129993
Lead sponsor
Daiichi Sankyo
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Aug 19, 2025
Start date
Sep 26, 2025
Primary completion
Jun 1, 2029 (estimated)
Completion
Jan 22, 2030 (estimated)
Last update
Aug 20, 2026

Study contacts

Contact for Trial Information
Contact
CTRinfo_us@daiichisankyo.com
908-992-6400

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Datopotamab deruxtecan

Start the discussion